1 inborn errors of metabolism (ieMs) are rare diseases produced by the accumulation of abnormal amounts of metabolites, toxic to the newborn. When not detected on time, they can lead to irreversible physiological and psychological sequels or even demise. Metabolomics has emerged as an efficient and powerful tool for ieM detection in newborns, children, and adults with late onset. in here, we screened urine samples from a large set of neonates (470 individuals) from a homogeneous population (Basque Country), for the identification of congenital metabolic diseases using NMR spectroscopy. Absolute quantification allowed to derive a probability function for up to 66 metabolites that adequately describes their normal concentration ranges in newborns from the Basque country. the absence of another 84 metabolites, considered abnormal, was routinely verified in the healthy newborn population and confirmed for all but 2 samples, of which one showed toxic concentrations of metabolites associated to ketosis and the other one a high trimethylamine concentration that strongly suggested an episode of trimethylaminuria. thus, a non-invasive and readily accessible urine sample contains enough information to assess the potential existence of a substantial number (>70) of IEMs in newborns, using a single, automated and standardized 1 H-nMR-based analysis.
NMR spectroscopy is well suited to characterize biofluids as it is a quantifiable, reproducible, non-selective and non-destructive and it is particularly adequate for the characterization of complex solutions (plasma, serum, urine, etc.) [6] [7] [8] , although is sensitivity is lower as compared to mass spectrometry. Consequently, NMR has already been applied to neonates with congenital metabolic diseases 9, 10 . 1 H-NMR spectroscopy successfully identified neonates carrying different inborn errors including phenylketonuria 11 , maple syrup urine disease 12 and errors of purine and pyrimidine metabolism 13 .
In 2014 a group of Turkish hospitals carried out a 1 H-NMR based clinical study where urine of more than 900 newborns was analyzed to derive the normal concentration ranges for up to 20 normal metabolites and 45 pathological metabolites involved in IEMs 14 . Here, we have implemented and expanded this methodology to conduct a clinical study on urine samples from 470 newborns, obtained from the four public hospitals with neonatology units in the Basque Country. Data analysis allowed to derive the normal metabolic profile of local newborns and to implement an automated screening routine to identify up to 75 congenital metabolic diseases that can be easily extrapolated to other geographical regions.
Results
Description of the data collection. Complete demographic data was collected for 470 neonates, except for two samples, with no pertaining metadata. After initial quality control, urine samples from 9 newborns were discarded because they showed centrifugation-resistant turbidity, a feature usually associated with bacterial contamination. The final dataset was composed of 461 samples.
More than 50% of the urine samples were collected at 2-3 days age (Table S1 ) and all samples were obtained from newborns with a birth weight above 2.5 Kg. The dominant ethnic group is Caucasian (>80%) and males and females were equally represented in the study. Gestational age, head circumference and feeding type varied largely (Table S1 ).
1 H-nMR spectra acquisition and multivariate analysis. Two different 1 H-NMR spectra were collected: a high-resolution 1D 1 H spectrum yielded quantitative metabolite data for statistical analysis and a 2D-Jres experiment assisted in peak assignment and metabolite identification. All spectra were collected at 300 K under strict SOPs (see Material and Methods) on either a 600 MHz Bruker AVANCE III (244 samples) or AVANCE IVDr (213 samples) spectrometer, where neither PCA nor PLS analyses revealed any statistical difference between both subsets (Fig. S1) .
The 1D 1 HNMR spectra were then automatically processed and integrated over segments of 0.01 ppm spectral width to obtain bin intensities for statistical analysis. A visual comparison identified six urine samples with poor spectral quality and water suppression that were discarded from further analysis. Using multivariate analysis, 7% of the samples presented multiple regions of the spectra with deviations from normality ( Fig. S2 ) and were no longer considered. This value is lower than previous equivalent studies 11 , and we attribute the discrepancy to the different number of engaged clinical partners and to an improved coordination with the hospitals.
For the remaining set of 437 urine samples, an initial PCA of bin intensities provided a first survey of the metabolomic data and unbiased rough sample clustering. Neither PCA nor PLS revealed any statistically significant differences between sample subsets from the different hospitals (Fig. 1) . Likewise, no correlation with other metadata was observed by PLS-DA except for gender and age at sample collection, for which a metabolic fingerprint is observed (Fig. S3) as reported previously 14 . A slight trend for clustering was observed as a function of head circumference (Fig. S3E) , consistent with previous results 15 . www.nature.com/scientificreports www.nature.com/scientificreports/ Targeted analysis: metabolite identification and quantification. Targeted analysis aims at quantifying a given set of metabolites. To that end, the chemical information associated with the bins in the 1D 1 H-NMR spectrum in combination with the multiplicity information extracted from the 2D J-resolved spectrum was combined to identify up to 150 metabolites in the urine spectrum (Table S2) . For each metabolite, the concentration was calculated both, absolute or relative to creatinine. Absolute quantification was referred to the TSP signal in the urine spectra, calculating a signal-intensity per-proton-ratio after the correction for several effects including molecular mass, number of protons, relaxation time, chemical shift, signal multiplicity and coupling constants, line width and Gauss-Lorentz ratio. To that end, signal was fitted using a simplex algorithm also looking for the ranges for signal detection and quantification. Quantification relative to creatinine (in mmol/mol creatinine) used the intensity ratio between a specified metabolite signal and the methyl signal of creatinine.
For a given metabolite, the limit of detection (LOD , Table S2 ) was determined via spiking experiments from an equivalently measured reference sample database and by simulating spectra after different concentrations of the analyte were added 14 . Averaging over the total cohort allows calculating the probability of obtaining a value above the LOD for the metabolite.
probabilistic models for the quantified metabolites. Of 150 metabolites considered, 58 always remained below their LOD (see Table S2 ) and where, therefore, never detected. Of the remaining 92 metabolites, 66 had a detection incidence of 2.5% or more, allowing to fit a distribution model. As a metabolite's LOD implies incomplete sampling of the underlying distribution with a natural skew towards higher metabolite concentrations, a generalized extreme value (GEV) distribution model was chosen for its inherent adaptability 16 . GEV is a probability distribution based on extreme value analysis (i. e. extreme deviations from the median of probability distributions) and it seeks to assess the probability of extreme events such as the skewed distributions for the quantified metabolites that considers the LOD values. Table S2 reports the derived distribution parameters for the 150 metabolites considered and the Q2.5 and Q97.5 quantiles (which delimit the range where 95% of samples are found) obtained from a GEV distribution model (calculated with Eq. 4) or directly from the data histogram. The quantile values obtained by both methods are in excellent agreement except for acetic acid, where the Q97.5 value from the GEV model (332) is larger than that from the data histogram (240) presumably due to the slightly more permissive ranges obtained with the model (Fig. S4) . Figure 2 shows 9 representative examples of metabolite concentration histograms along with modeled probability densities from a GEV distribution that fit well to the experimental data regardless of the detection frequency and the histogram shape (the data for all traceable 66 metabolites with a detection frequency larger than 2.5% is shown in Fig. S4 ). Thus, the protocol for model building presented here can be applied to derive the normal metabolite concentrations in newborn urine samples for the general population in the Basque Country and to reveal significant deviations as a strong indication for a genetic disorder associated to the pertaining metabolite.
Diagnostic value of the investigated metabolites. Out of the 150 metabolites determined in the urine samples (Table S2 ), 7 derive from contaminations from the matrix used (diaper and the plastic consumables), www.nature.com/scientificreports www.nature.com/scientificreports/ 19 metabolites are associated with bacterial contamination, likely during the sample collection, 14 metabolites derive from drug catabolism (active principles or excipients) and 12 metabolites are associated to the mother's diet (i. e. caffeine). These metabolites contain little diagnostic nor therapeutic information, but provide metadata information and potential insight on the bacterial gut microbiota of the newborn.
The remaining set of 98 relevant metabolites have been associated with inborn errors of metabolism (IEMs) and, therefore, have potential diagnostic value for the 75 diseases and unhealthy conditions summarized in Table 1 . The metabolites are numbered as shown in Table S2 . Most commonly, an IEM produces alterations for several metabolites where the "reference metabolites" listed in Table 1 are those required to unambiguously identify an IEM, according to the seminal work of Wevers 17 and others 18 . Yet, as many metabolites can show abnormal concentrations due to different IEMs, their specific range values (if available, e.g., from HMBD, Metagene) are reported in Table S2 . These "support metabolites" are also related to a disorder and can, thus, further confirm an IEM or help to differentiate between related IEMs. Finally, for metabolites that occur in the urine of both healthy and IEM affected newborns, the modeled GEV distributions can be used to determine the probability for our 1 H NMR based test to indicate a potential IEM case in the Basque Country (F global listed in Table 1 ). Such value corresponds to the frequency probability of finding a newborn with a concentration above the pathogenic threshold value. In cases where more than one metabolite showed up with a diagnostic distribution for a given IEM, the larger value of F global was used for indication.
Metabolic disorders detected within the cohort. In at least two newborn urine samples, we found abnormal concentrations of metabolites related to an alteration in the ketonic bodies. The first sample showed concentrations of 3-hydroxybutyric acid (240 mmol/mol creat), acetone, (210 mmol/mol creat), and acetoacetic acid (62 mmol/mol creat) far above their upper limits derived from the modeled distributions, with probabilities of 0.002, 0.0012, and <0.0001, respectively. Moreover, these metabolite concentrations were also higher than states as normal in metabolomics databases (HMDB, Metagene). The second sample likewise showed abnormally high concentrations for 3-hydroxybutyric acid (170 mmol/mol creat, probability 0.0124) and acetoacetic acid (49 mmol/mol creat, probability 0.0004), which were accompanied by an elevated glucose concentration (560 mmol/mol creat, probability 0.0083). Taken together, these experimental results strongly suggest two cases of ketosis that might be related to a transition state of the newborn.
Finally, a third newborn presented high levels of trimethylamine (24 mmol/mol creatinine; probability 0.0014) suggesting the IEM Trimethylaminuria (FMO3) since the normal concentrations in newborns, as determined in our 1 H NMR study (Fig. 2) , are not higher than 6 mmol/mol creat. Yet, this finding should be accompanied by elevated concentrations TMAO, currently unavailable within our method.
Discussion
In this contribution we have investigated novel strategies for an early identification of congenital metabolopathies from 1 H NMR data from newborn urine samples. Even though IEMs are individually considered as rare disorders, their collective incidence is considerable and represents a serious public health problem. An early diagnosis of these pathologies is crucial to avoid serious acute symptoms and/or to avoid a lifelong treatment of patients. In the context of personalized medicine, even a negative (unsuspicious) result of such IEM tests still produces relevant data that can be integrated in a personal database together with molecular data which is expected to gain diagnostic value in the future.
In the last years had been increasing the number of IEM (around 50) that can be detected using mass spectrometry 19 , even though that the high sensitivity of the technique suggests that this number will increase. Moreover, MS requires the collection of dried blood spots (DBS), which is done by pricking the heel of newborns. It is easy to perform but the process is in a certain way invasive. In NMR spectroscopy, currently 75 IEMs may be detected and this number is also increasing over time. In here, up to 1000 urine metabolites are analyzed simultaneously in a measurement that avoids pricking and takes only minutes. In summary, compared to other techniques such as MS, NMR spectroscopy has great potential for newborn screening, as it is able to sample the metabolic profile and detect both known and unknown metabolites in a quantitative and non-targeted way. Moreover, it is reproducible, and the quantification of urine metabolites is independent on the instrument configuration as long as the SOPs are followed. Finally, the measurement is economically advantageous since the comprehensive metabolite set is already obtained. All these aspects position the technique in a leading place for a potential implementation of the methodology in hospitals and health centers for the screening of large population segments.
Using the metabolomics data provided from the whole cohort of newborns along with statistical analysis, we were able to create a healthy metabolome profile at a high degree of precision. A subset of 66 of the analyzed metabolites were found present in at least 2.5% of all the newborns. Normal ranges for these common metabolites have been established using automatic quantification, as shown in Figs S4-S6, and Table S2 , also compared to the normal and pathogenic levels reported in the literature. Some metabolites showing close proximity (or partial overlap) between normal and pathogenic concentrations reflect a heterogenic origin for the metabolite or an incomplete understanding of the relationship between the metabolite and the disease.
IEM incidence strongly depends on geographical and ethnic background of a population 20 and it is instructive to compare our model with the Turkish model previously reported 14 . The metabolites found in our study enclose 18 out of the 20 found in the Turkish work, while myo-Inositol and trimethylamine are found very often only in the Turkey model. We attribute such discrepancy to an improved identification of the two metabolites in our deconvolution algorithm.
Another 84 metabolites that are typically not found at NMR detectable level in healthy newborns were validated for their absence. Finally, we were also able to observe metabolites from different sources of contamination. Propylene glycol was present in about half of the urine samples likely from external manipulation. www.nature.com/scientificreports www.nature.com/scientificreports/ alcohol is a chemical included in cosmetics, skin conditioning also found in medication 21 . Moreover, the metabolite acetoin (present in perfumes) was observed in a few spectra from the same hospital (Fig. S2) , while unknown metabolites could be detected in a subset of the spectra as well. A future goal is to proceed with the identification of unknown peaks, to determine whether they contain potentially diagnostic information.
Deviations from normality in some of those common metabolites provide very useful information about rare and prevalent metabolic disorders. Up to 75 IEMs may potentially be detected based on the quantification of a single metabolite or the combination of several of them (Table 1) . Such disorders can be divided into urea cycle disorders, organic acidurias, purine/pyrimidine disorders, amino acidurias, carbohydrate disorders, creatine deficiencies, fatty acid oxidation disorders and other diseases and syndromes. For example, elevated concentrations of 3-hydroxybutyric acid, acetone and acetoacetic acid revealed a couple of ketosis cases (Fig. 3) . Ketosis is a metabolic state where the newborns use fat as fuel in preference to carbohydrates. The body makes ketones from fat, when dietary glucose (from carbohydrates and sugar) is low. Acetoacetate is one of the products of fatty acid oxidation and acetone and hydroxybutyrate are formed from acetoacetate 22 . In one case, the metabolic alteration was accompanied by high levels of glucose, an indicator of Insuline-dependant diabetes Mellitus. In another unrelated sample, a case of trimethylaminuria was also potentially identified. Hence, this approach has proven very useful for the discrimination of pathological samples by identifying abnormal metabolite concentrations or www.nature.com/scientificreports www.nature.com/scientificreports/ patterns after comparison with the model. Unfortunately, the samples were codified and anonymized so clinicians did not have the opportunity to follow the babies that showed these abnormal metabolites.
The number of samples analyzed constitute a limitation in our study: approximately 1:1000 neonates may be affected by a congenital metabolic disorder worldwide. In this context, analyzing less than 500 samples, we were able to detect up to three different metabolopathies, showing the method's potential. Yet, a higher number of samples will be needed to further validate the analytical technique.
In summary, the characterization of a large set of samples prompted us to develop a statistical model for several metabolites applicable to the healthy Basque Country newborn population. The model allows the identification of 75 different IEMs based on the comparative analysis of the absolute concentration of metabolites from a test sample in the context of the normal values obtained by the model which, in correlation with clinical parameters, allows the diagnosis and eventually the monitoring of patients throughout their illness 23 . The reasonable agreement with the number of metabolites and the concentration ranges found in other regions (i. e. Turkey) underline the idea that the model can be easily extrapolated to multiple regions, ultimately constituting a reliable alternative to the heel test for IEMs premature detection.
Methods
Study design. Urine samples were collected from 470 individuals that were born in one of the four public hospitals of the Basque Country with neonatology units: Cruces (Barakaldo, Bizkaia), Txagorritxu (Vitoria, Araba), Basurto (Bilbao, Bizkaia) & Donostia (Donostia, Guipuzkoa). All samples were codified and anonymized to protect the confidentiality of individual participants. nMR measurements. For each sample, a one-dimensional (1D) 1 H-NMR spectrum with water peak suppression 24 , and a 2D Jres experiment were collected at 300 K, using the Standard Operating Procedures described in the Supplementary Materials and Methods.
Statistical analysis. Outliers were properly identified and eliminated from the dataset. Multivariate and univariate statistics was applied to the dataset as explained in the Supplementary Materials and Methods.
Generalized extreme value distributions. The GEV distributions can be described by three parameters (location μ, scale σ, and shape ξ) and provide different levels of information. As usual in probability distributions, the cumulative distribution function (CDF) gives the probability of obtaining a value (concentration in this case) that is lower or equal than a specific threshold x. The CDF (F GEV ) for a GEV distribution can be calculated according to the following expression where s is the scaled value of x (s = (x − μ)/σ). Similarly, it is possible to calculate the probability of obtaining a concentration higher than x using the complementary CDF ( = − F F 1 GEV G EV ). Due to LOD, F GEV was in fact incomplete because the fraction of samples below LOD had to be considered and the global CDF (F global ) was calculated with the following expression
global GEV where λ is the fraction of samples above LOD. From this expression is straightforward to deduce that
global GEV
Moreover, since the CDF is invertible it is also possible to calculate specific concentrations associated to quantiles using function Q GEV , as shown in Eq. 4: 
where p is the quantile for which is wanted to obtain its associated concentration. It is also affected by incompleteness of CDF due to LOD. For this reason, quantile q must be adjusted as follows:
where the numerator calculates the amount of quantile p that is not covered by the fraction below LOD (1 − λ) and the numerator scales this result in the context of the modeled GEV.
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